Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Tissue Disposition and Pharmacokinetics of Recombinant Human Nerve Growth Factor after Acute and Chronic Subcutaneous Administration in Monkeys

Cindy B. Nguyen, Louise Harris, Éva Szönyi, Sharon A. Baughman, Victoria G. Hale, Noël O. Dybdal, Michael D. Sadick and Enrique Escandón
Drug Metabolism and Disposition May 2000, 28 (5) 598-607;
Cindy B. Nguyen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louise Harris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Éva Szönyi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon A. Baughman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victoria G. Hale
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noël O. Dybdal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael D. Sadick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enrique Escandón
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In this study, we have characterized the metabolism, tissue disposition, excretion routes, and plasma pharmacokinetics of recombinant human nerve growth factor after single and multiple s.c. administration in male cynomolgus monkeys. Unlabeled nerve growth factor (NGF; 2 mg/kg) was administered three times a week for 4 weeks and a full pharmacokinetic profile was obtained for doses 1 and 12. For the tissue distribution studies, 0.8 μg/kg of trace125I-labeled recombinant human nerve growth factor was dosed. Histological analysis of emulsion-microautoradiography indicated that specific 125I-NGF labeling was confined to sections of nerves most frequently localized adjacent to large vessels in sections of kidney, spleen, liver, and salivary gland. A small percentage of large neurons within the sympathetic ganglia were intensely labeled, as well as large neurons within the dorsal root ganglia. We found an increased disposition of 125I-NGF in parts of the peripheral nervous system (including sympathetic ganglia) from 8 to 24 h postdose. In contrast, radioactivity in most non-neuronal tissues declined. This suggests specific uptake in these target tissues known to express specific receptors for NGF. We also identified changes in pharmacokinetic parameters after single versus chronic s.c. administration. These studies demonstrated that s.c. administration of NGF at 0.8 μg/kg doses in monkeys is capable of accessing and localizing in the target tissues.

Footnotes

  • Send reprint requests to: Enrique Escandón, Ph.D., Dept. of Pharmacokinetics and Metabolism, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. E-mail: quique{at}gene.com

  • This work was supported by Genentech, Inc.

  • Abbreviations used are::
    NGF
    nerve growth factor
    rhNGF
    recombinant human nerve growth factor
    trkA
    receptor tyrosine kinase
    PK
    pharmacokinetic
    PAGE
    polyacrylamide gel electrophoresis
    ELISA
    enzyme-linked immunosorbent assay
    KIRA
    kinase receptor activation assay
    TCA
    trichloroacetic acid
    DRG
    dorsal root ganglia
    CNS
    central nervous system
    PNS
    peripheral nervous system
    Cmax
    maximum observed rhNGF plasma concentration
    Vz/F
    central volume of distribution
    • Received June 1, 1999.
    • Accepted January 27, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 28 (5)
Drug Metabolism and Disposition
Vol. 28, Issue 5
1 May 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Tissue Disposition and Pharmacokinetics of Recombinant Human Nerve Growth Factor after Acute and Chronic Subcutaneous Administration in Monkeys
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Tissue Disposition and Pharmacokinetics of Recombinant Human Nerve Growth Factor after Acute and Chronic Subcutaneous Administration in Monkeys

Cindy B. Nguyen, Louise Harris, Éva Szönyi, Sharon A. Baughman, Victoria G. Hale, Noël O. Dybdal, Michael D. Sadick and Enrique Escandón
Drug Metabolism and Disposition May 1, 2000, 28 (5) 598-607;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Tissue Disposition and Pharmacokinetics of Recombinant Human Nerve Growth Factor after Acute and Chronic Subcutaneous Administration in Monkeys

Cindy B. Nguyen, Louise Harris, Éva Szönyi, Sharon A. Baughman, Victoria G. Hale, Noël O. Dybdal, Michael D. Sadick and Enrique Escandón
Drug Metabolism and Disposition May 1, 2000, 28 (5) 598-607;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • A PBPK model for CBD in adults and children
  • Olanzapine Glucuronidation in Humanized Mice
  • rs2242480 Regulates the Expression of CYP3A4 and CYP3A5
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics